Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan
Current Oncology · 10.01.2025 · 32 (1) · 36
DOI: 10.3390/curroncol32010036 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Current Oncology, online erschienen am 10.01.2025. Verfasst von Jerry Shu-Hung Kuo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City 640, Taiwan. Hauptthemen laut MEDLINE: Afatinib, Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Taiwan University Hospital Yunlin Branch.
Abstract (Originalsprache)
Background
Afatinib and Osimertinib are first-line treatments for EGFR-mutated advanced non-small cell lung cancer (NSCLC), but their comparative efficacies and the patient groups that benefit the most remain unclear. This multicenter retrospective study evaluated the efficacy of first-line Afatinib and Osimertinib in NSCLC patients with EGFR 19del and no brain metastases at diagnosis.
Methods
The primary endpoints were time on treatment (ToT) and overall survival (OS). Survival analyses were performed for three groups: Afatinib followed by Osimertinib, Afatinib followed by other therapies, and Osimertinib (alone or followed by other therapies). Rebiopsy practices, including T790M mutation detection, were also analyzed in patients with disease progression on Afatinib.
Results
Among 97 Afatinib-treated and 60 Osimertinib-treated patients, Osimertinib showed a significantly longer ToT (23.3 vs. 16.5 months; p = 0.007). Median OS was numerically higher for Afatinib with sequential Osimertinib (40.5 vs. 34.6 months for Osimertinib; p = 0.473). Osimertinib demonstrated advantages, with fewer brain metastases upon progression and fewer adverse effects. In the Afatinib group, 64% of patients with disease progression underwent rebiopsy, with 39% testing positive for T790M mutation and subsequently receiving Osimertinib. Rebiopsy was most frequently performed on the lung parenchyma using non-surgical methods.
Conclusions
In this real-world study, Osimertinib achieved a significantly longer ToT compared to Afatinib in NSCLC patients with EGFR 19del and no brain metastases. The sequential use of Afatinib followed by Osimertinib showed a trend toward improved OS, highlighting the importance of rebiopsy for identifying T790M mutations to guide subsequent therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City 640, Taiwan.
- Division of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City 220, Taiwan.
- Department of Nursing, Cardinal Tien Junior College of Healthcare and Management, New Taipei City 231, Taiwan.
- Division of Chest Medicine, Department of Internal Medicine, National Yang-Ming Chiao Tung University Hospital, Yilan County, Yilan City 260, Taiwan.
- Department of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung City 824, Taiwan.
- School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung City 824, Taiwan.
ORCID-Profile: Jerry Shu-Hung Kuo, Shih-Chieh Chang, Yu-Feng Wei, Chung-Yu Chen
Förderung
- National Taiwan University Hospital Yunlin Branch
Zitieren
APA
Kuo, J. S., Chang, C. Y., Chang, S. C., Wei, Y. F., & Chen, C. Y. (2025). Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. Current Oncology, 32(1), 36. https://doi.org/10.3390/curroncol32010036
Vancouver
Kuo JS, Chang CY, Chang SC, Wei YF, Chen CY. Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan. Current Oncology. 2025;32(1):36. doi:10.3390/curroncol32010036
BibTeX
@article{Kuo2025,
author = {Kuo, Jerry Shu-Hung and Chang, Cheng-Yu and Chang, Shih-Chieh and Wei, Yu-Feng and Chen, Chung-Yu},
title = {Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan},
journal = {Current Oncology},
year = {2025},
volume = {32},
number = {1},
pages = {36},
doi = {10.3390/curroncol32010036}
}
EUVIMED